News

Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 third quarter on Tuesday, May 3, 2022, at approximately 6:30 a.m. ET. The company will also

Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa^® allowed patients to achieve

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that its Board of Directors has named Christopher Hunter as the Company’s new Chief Executive Officer. He will join Acadia on April

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management

Recordati Rare Diseases announce today the publication of positive results from the Phase III LINC 4 study of Isturisa in The Journal of Clinical Endocrinology & Metabolism.¹ These data reinforce

Recordati Rare Diseases gibt heute die Veröffentlichung der positiven Ergebnisse der Phase-III-Studie LINC 4 zu Isturisa im The Journal of Clinical Endocrinology & Metabolism.¹ bekannt. Diese Daten

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it will appoint Flavia H. Pease as its next Chief Financial Officer, succeeding David R. Smith, who previously

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220327005085/en/

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

CSL

Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, will present updated results from

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today marked World TB Day by announcing its QuantiFERON blood test has been used to screen patients for tuberculosis (TB) infection more than

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute anlässlich des Welttuberkulosetages bekannt, dass sein QuantiFERON-Bluttest seit seiner Markteinführung mehr als 100 Millionen Mal

Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 pivotal INNOVATE-3 study evaluating the safety and efficacy of Tumor Treating Fields

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006149/en/

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

CSL

AMN Healthcare, the nation’s leader in total talent solutions for healthcare organizations, has been named to America’s 100 Most Sustainable Companies by Barron’s magazine.

“The AMN team and our